Drug profile · INN
perindopril erbumine
PERINDOPRIL ERBUMINE
perindopril erbumine (PERINDOPRIL ERBUMINE) is a angiotensin-converting enzyme inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — perindopril erbumine
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
perindopril erbumine (PERINDOPRIL ERBUMINE) is a angiotensin-converting enzyme inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Angiotensin-converting enzyme inhibitor
Primary target: Angiotensin-converting enzyme
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is perindopril erbumine?
perindopril erbumine (PERINDOPRIL ERBUMINE) is a angiotensin-converting enzyme inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for perindopril erbumine?
PERINDOPRIL ERBUMINE is a marketed brand name for perindopril erbumine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of perindopril erbumine?
perindopril erbumine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.